Claims for Patent: 5,691,336

Summary for Patent: 5,691,336

Title:	Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
Abstract:	Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
Inventor(s):	Dorn; Conrad P. (Plainfield, NJ), Hale; Jeffrey J. (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ)
Assignee:	Merck & Co., Inc. (Rahway, NJ)
Application Number:	08/525,870
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 5,691,336
Patent Claims:	1. A compound of structural formula: ##STR14## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from: (i) hydrogen, (ii) C.sub.1-6 alkyl, (iii) hydroxy-C.sub.1-6 alkyl, and (iv) phenyl, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9, (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, (j) --CO.sub.2 R.sup.9 ; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, (j) --NR.sup.9 COR.sup.10, (k) --NR.sup.9 CO.sub.2 R.sup.10, (l) --CONR.sup.9 R.sup.10, (m) --CO.sub.2 NR.sup.9 R.sup.10, (n) --COR.sup.9, and (o) --CO.sub.2 R.sup.9 ; or the groups R.sup.2 and R.sup.3 are joined together to form a carbocyclic ring selected from the group consisting of: (a) cyclopentyl, (b) cyclohexyl, (c) phenyl, and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from: (i) C.sub.1-6 alkyl, (ii) C.sub.1-6 alkoxy, (iii) --NR.sup.9 R.sup.10, (iv) halo, and v) trifluoromethyl; or the groups R.sup.2 and R.sup.3 are joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) furanyl, (g) oxazolyl, (h) thienyl, and (i) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, (v) halo, and (vi) trifluoromethyl; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9 ; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, and (j) --CO.sub.2 R.sup.9 ; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (j) --NR.sup.9 COR.sup.10, (k) --NR.sup.9 CO.sub.2 R.sup.10, (l) --CONR.sup.9 R.sup.10, (m) --CO.sub.2 NR.sup.9 R.sup.10, (n) --COR.sup.9, and (o) --CO.sub.2 R.sup.9 ; (6) halo, (7) --CN, (8) --CF.sub.3, (9) --NO.sub.2, (10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-5 alkyl, (11) --SOR.sup.14, (12) --SO.sub.2 R.sup.14, (13) NR.sup.9 COR.sup.10, (14) CONR.sup.9 COR.sup.10, (15) NR.sup.9 R.sup.10, (16) NR.sup.9 CO.sub.2 R.sup.10, (17) hydroxy, (18) C.sub.1-6 alkoxy, (19) COR.sup.9, (20) CO.sub.2 R.sup.9, (21) 2-pyridyl, (22) 3-pyridyl, (23) 4-pyridyl, (24) 5-tetrazolyl, (25) 2-oxazolyl, and (26) 2-thiazolyl; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8, or --OX; A is selected from the group consisting of: (1) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, wherein halo is fluoro, chloro, bromo or iodo, (h) --NR.sup.9 R.sup.10, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9 ; (2) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, and (j) --CO.sub.2 R.sup.9 ; and (3) C.sub.2-6 alkynyl; B is a heterocycle, wherein the heterocycle is selected from the group consisting of: ##STR15## and wherein the heterocycle is substituted in addition to --X with one or more substituent(s) selected from: (i) hydrogen; (ii) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (iii) C.sub.1-6 alkoxy, (iv) oxo, (v) hydroxy, (vi) thioxo, (vii) --SR.sup.9, (viii) halo, (ix) cyano, (x) phenyl, (xi) trifluoromethyl, (xii) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (xiii) --NR.sup.9 COR.sup.10, (xiv) --CONR.sup.9 R.sup.10, (xv) --CO.sub.2 R.sup.9, and (xvi) --(CH.sub.2).sub.m --OR.sup.9 ; p is 0 or 1; X is selected from: (a) --PO(OH)O.sup.- .cndot.M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, (b) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, (c) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion, (d) --CH(R.sup.4)--PO(OH)O.sup.- .cndot.M.sup.+, wherein R.sup.4 is hydrogen or C.sub.1-3 alkyl, (e) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.2M.sup.+, (f) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.D.sup.2+, (g) --SO.sub.3.sup.- .cndot.M+, (h) --CH(R.sup.4)--SO.sub.3.sup.- .cndot.M.sup.+, (i) --CO--CH.sub.2 CH.sub.2 --CO.sub.2.sup.- .cndot.M.sup.+, (j) --CH(CH.sub.3)--O--CO--R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR16## (k) hydrogen, with the proviso that if p is 0 and none of R.sup.11, R.sup.12 or R.sup.13 are --OX, then X is other than hydrogen; Y is selected from the group consisting of: (1) a single bond, (2) --O--, (3) --S--, (4) --CO--, (5) --CH.sub.2 --, (6) --CHR.sup.15 --, and (7) --CR.sup.15 R.sup.16 --, wherein R.sup.15 and R.sup.16 are independently selected from the group consisting of: (a) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (i) hydroxy, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) phenyl-C.sub.1-3 alkoxy, (v) phenyl, (vi) --CN, (vii) halo, (viii) --NR.sup.9 R.sup.10, (ix) --NR.sup.9 COR.sup.10, (x) --NR.sup.9 CO.sub.2 R.sup.10, (xi) --CONR.sup.9 R.sup.10, (xii) --COR.sup.9, and (xiii) --CO.sub.2 R.sup.9 ; (b) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (i) hydroxy, (ii) C.sub.1-6 alkoxy, (iii) C.sub.1-6 alkyl, (iv) C.sub.2-5 alkenyl, (v) halo, (vi) --CN, (vii) --NO.sub.2, (viii) --CF.sub.3, (ix) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (x) --NR.sup.9 COR.sup.10, (xi) --NR.sup.9 CO.sub.2 R.sup.10, (xii) --CONR.sup.9 R.sup.10, (xiii) --CO.sub.2 NR.sup.9 R.sup.10, (xiv) --COR.sup.9, and (xv) --CO.sub.2 R.sup.9 ; Z is selected from: (1) hydrogen, (2) C.sub.1-6 alkyl, and (3) hydroxy, with the proviso that if Y is --O--, then Z is other than hydroxy, and with the further proviso that if Y is --CHR.sup.15 --, then Z and R.sup.15 may be joined together to form a double bond between the two carbon atoms. 2. The compound of claim 1 wherein: R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, (3) C.sub.2-6 alkenyl, and (4) phenyl; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, (3) fluoro, (4) chloro, (5) bromo, (6) iodo, and (7) --CF.sub.3 ; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the group consisting of: (1) fluoro, (2) chloro, (3) bromo, and (4) iodo; A is unsubstituted C.sub.1-6 alkyl; B is selected from the group consisting of: ##STR17## p is 0; X is selected from: (a) --PO(OH)O.sup.- .cndot.M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, (b) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, (c) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion, (d) --CH(R.sup.4)--PO(OH)O.sup.- .cndot.M.sup.+, wherein R.sup.4 is hydrogen or methyl, (e) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.2M.sup.+, (f) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.D.sup.2+, (g) --CO--CH.sub.2 CH.sub.2 --CO.sub.2.sup.- .cndot.M.sup.+, (h) --CH(CH.sub.3)--O--CO--R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR18## and Y is --O--; Z is hydrogen or C.sub.1-4 alkyl. 3. The compound of claim 1 wherein Z is C.sub.1-4 alkyl. 4. the compound of claim 1 wherein Z is --CH.sub.3. 5. The compound of claim 1 wherein A is --CH.sub.2 -- or --CH(CH.sub.3)--. 6. The compound of claim 1 wherein --B is selected from the group consisting of: ##STR19## 7. The compound of claim 1 wherein --A--B is selected from the group consisting of: ##STR20## 8. The compound of claim 1 wherein X is selected from the group consisting of: (a) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, and (b) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion. 9. The compound of claim 1 of the structural formula II: ##STR21## or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 of the structural formula III: ##STR22## or a pharmaceutically acceptable salt thereof. 11. A compound which is selected from the group consisting of: (1) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo-1H,4H-1 ,2,4-triazolo)methyl)morpholine N-oxide; (2) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (3) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (4) 2-(R)-1(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl -4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (5) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-4-fluoro)-pheny l-4-(3-(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine; (6) 2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine; or a pharmaceutically acceptable salt thereof. 12. The compound of claim 11 wherein the pharmaceutically acceptable salt is the bis(N-methyl-D-glucamine) salt. 13. A compound which is selected from the group consisting of: ##STR23## wherein K.sup.+ is a pharmaceutically acceptable counterion. 14. A compound which is: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl -4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methylmorpholine; or a pharmaceutically acceptable salt thereof. 15. The compound of claim 14 wherein the pharmaceutically acceptable salt is the bis(N-methyl-D-glucamine) salt. 16. A compound which is 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl -4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine). 17. A compound which is: ##STR24## wherein K.sup.+ is a pharmaceutically acceptable counterion. 18. The compound of claim 17 wherein K.sup.+ is N-methyl-D-glucamine. 19. A compound which is: ##STR25## 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the compound of claim 1. 21. The pharmaceutical composition of claim 20 wherein the pharmaceutically acceptable carrier comprises water. 22. The pharmaceutical composition of claim 20 wherein the pharmaceutically acceptable carrier comprises a physiologically acceptable saline solution. 23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound which is: ##STR26## 24. A method for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal which comprises the administration to the mammal of the compound of claim 1 in an amount that is effective for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in the mammal. 25. A method of treating or preventing pain or nociception which comprises the administration to the mammal of an effective amount of the compound of claim 1. 1. A compound of structural formula: ##STR14## or a pharmaceutically acceptable salt thereof, wherein: R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, wherein R.sup.9 and R.sup.10 are independently selected from: (i) hydrogen, (ii) C.sub.1-6 alkyl, (iii) hydroxy-C.sub.1-6 alkyl, and (iv) phenyl, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9, (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, (j) --CO.sub.2 R.sup.9 ; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, wherein m is 0, 1 or 2, (j) --NR.sup.9 COR.sup.10, (k) --NR.sup.9 CO.sub.2 R.sup.10, (l) --CONR.sup.9 R.sup.10, (m) --CO.sub.2 NR.sup.9 R.sup.10, (n) --COR.sup.9, and (o) --CO.sub.2 R.sup.9 ; or the groups R.sup.2 and R.sup.3 are joined together to form a carbocyclic ring selected from the group consisting of: (a) cyclopentyl, (b) cyclohexyl, (c) phenyl, and wherein the carbocyclic ring is unsubstituted or substituted with one or more substituents selected from: (i) C.sub.1-6 alkyl, (ii) C.sub.1-6 alkoxy, (iii) --NR.sup.9 R.sup.10, (iv) halo, and v) trifluoromethyl; or the groups R.sup.2 and R.sup.3 are joined together to form a heterocyclic ring selected from the group consisting of: (a) pyrrolidinyl, (b) piperidinyl, (c) pyrrolyl, (d) pyridinyl, (e) imidazolyl, (f) furanyl, (g) oxazolyl, (h) thienyl, and (i) thiazolyl, and wherein the heterocyclic ring is unsubstituted or substituted with one or more substituent(s) selected from: (i) C.sub.1-6 alkyl, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) --NR.sup.9 R.sup.10, (v) halo, and (vi) trifluoromethyl; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen; (2) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --NR.sup.9 R.sup.10, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9 ; (3) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, and (j) --CO.sub.2 R.sup.9 ; (4) C.sub.2-6 alkynyl; (5) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) C.sub.1-6 alkoxy, (c) C.sub.1-6 alkyl, (d) C.sub.2-5 alkenyl, (e) halo, (f) --CN, (g) --NO.sub.2, (h) --CF.sub.3, (i) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (j) --NR.sup.9 COR.sup.10, (k) --NR.sup.9 CO.sub.2 R.sup.10, (l) --CONR.sup.9 R.sup.10, (m) --CO.sub.2 NR.sup.9 R.sup.10, (n) --COR.sup.9, and (o) --CO.sub.2 R.sup.9 ; (6) halo, (7) --CN, (8) --CF.sub.3, (9) --NO.sub.2, (10) --SR.sup.14, wherein R.sup.14 is hydrogen or C.sub.1-5 alkyl, (11) --SOR.sup.14, (12) --SO.sub.2 R.sup.14, (13) NR.sup.9 COR.sup.10, (14) CONR.sup.9 COR.sup.10, (15) NR.sup.9 R.sup.10, (16) NR.sup.9 CO.sub.2 R.sup.10, (17) hydroxy, (18) C.sub.1-6 alkoxy, (19) COR.sup.9, (20) CO.sub.2 R.sup.9, (21) 2-pyridyl, (22) 3-pyridyl, (23) 4-pyridyl, (24) 5-tetrazolyl, (25) 2-oxazolyl, and (26) 2-thiazolyl; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the definitions of R.sup.6, R.sup.7 and R.sup.8, or --OX; A is selected from the group consisting of: (1) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, wherein halo is fluoro, chloro, bromo or iodo, (h) --NR.sup.9 R.sup.10, (i) --NR.sup.9 COR.sup.10, (j) --NR.sup.9 CO.sub.2 R.sup.10, (k) --CONR.sup.9 R.sup.10, (l) --COR.sup.9, and (m) --CO.sub.2 R.sup.9 ; (2) C.sub.2-6 alkenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (a) hydroxy, (b) oxo, (c) C.sub.1-6 alkoxy, (d) phenyl-C.sub.1-3 alkoxy, (e) phenyl, (f) --CN, (g) halo, (h) --CONR.sup.9 R.sup.10, (i) --COR.sup.9, and (j) --CO.sub.2 R.sup.9 ; and (3) C.sub.2-6 alkynyl; B is a heterocycle, wherein the heterocycle is selected from the group consisting of: ##STR15## and wherein the heterocycle is substituted in addition to --X with one or more substituent(s) selected from: (i) hydrogen; (ii) C.sub.1-6 alkyl, unsubstituted or substituted with halo, --CF.sub.3, --OCH.sub.3, or phenyl, (iii) C.sub.1-6 alkoxy, (iv) oxo, (v) hydroxy, (vi) thioxo, (vii) --SR.sup.9, (viii) halo, (ix) cyano, (x) phenyl, (xi) trifluoromethyl, (xii) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (xiii) --NR.sup.9 COR.sup.10, (xiv) --CONR.sup.9 R.sup.10, (xv) --CO.sub.2 R.sup.9, and (xvi) --(CH.sub.2).sub.m --OR.sup.9 ; p is 0 or 1; X is selected from: (a) --PO(OH)O.sup.- .cndot.M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, (b) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, (c) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion, (d) --CH(R.sup.4)--PO(OH)O.sup.- .cndot.M.sup.+, wherein R.sup.4 is hydrogen or C.sub.1-3 alkyl, (e) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.2M.sup.+, (f) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.D.sup.2+, (g) --SO.sub.3.sup.- .cndot.M+, (h) --CH(R.sup.4)--SO.sub.3.sup.- .cndot.M.sup.+, (i) --CO--CH.sub.2 CH.sub.2 --CO.sub.2.sup.- .cndot.M.sup.+, (j) --CH(CH.sub.3)--O--CO--R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR16## (k) hydrogen, with the proviso that if p is 0 and none of R.sup.11, R.sup.12 or R.sup.13 are --OX, then X is other than hydrogen; Y is selected from the group consisting of: (1) a single bond, (2) --O--, (3) --S--, (4) --CO--, (5) --CH.sub.2 --, (6) --CHR.sup.15 --, and (7) --CR.sup.15 R.sup.16 --, wherein R.sup.15 and R.sup.16 are independently selected from the group consisting of: (a) C.sub.1-6 alkyl, unsubstituted or substituted with one or more of the substituents selected from: (i) hydroxy, (ii) oxo, (iii) C.sub.1-6 alkoxy, (iv) phenyl-C.sub.1-3 alkoxy, (v) phenyl, (vi) --CN, (vii) halo, (viii) --NR.sup.9 R.sup.10, (ix) --NR.sup.9 COR.sup.10, (x) --NR.sup.9 CO.sub.2 R.sup.10, (xi) --CONR.sup.9 R.sup.10, (xii) --COR.sup.9, and (xiii) --CO.sub.2 R.sup.9 ; (b) phenyl, unsubstituted or substituted with one or more of the substituent(s) selected from: (i) hydroxy, (ii) C.sub.1-6 alkoxy, (iii) C.sub.1-6 alkyl, (iv) C.sub.2-5 alkenyl, (v) halo, (vi) --CN, (vii) --NO.sub.2, (viii) --CF.sub.3, (ix) --(CH.sub.2).sub.m --NR.sup.9 R.sup.10, (x) --NR.sup.9 COR.sup.10, (xi) --NR.sup.9 CO.sub.2 R.sup.10, (xii) --CONR.sup.9 R.sup.10, (xiii) --CO.sub.2 NR.sup.9 R.sup.10, (xiv) --COR.sup.9, and (xv) --CO.sub.2 R.sup.9 ; Z is selected from: (1) hydrogen, (2) C.sub.1-6 alkyl, and (3) hydroxy, with the proviso that if Y is --O--, then Z is other than hydroxy, and with the further proviso that if Y is --CHR.sup.15 --, then Z and R.sup.15 may be joined together to form a double bond between the two carbon atoms. 2. The compound of claim 1 wherein: R.sup.2 and R.sup.3 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, (3) C.sub.2-6 alkenyl, and (4) phenyl; R.sup.6, R.sup.7 and R.sup.8 are independently selected from the group consisting of: (1) hydrogen, (2) C.sub.1-6 alkyl, (3) fluoro, (4) chloro, (5) bromo, (6) iodo, and (7) --CF.sub.3 ; R.sup.11, R.sup.12 and R.sup.13 are independently selected from the group consisting of: (1) fluoro, (2) chloro, (3) bromo, and (4) iodo; A is unsubstituted C.sub.1-6 alkyl; B is selected from the group consisting of: ##STR17## p is 0; X is selected from: (a) --PO(OH)O.sup.- .cndot.M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, (b) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, (c) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion, (d) --CH(R.sup.4)--PO(OH)O.sup.- .cndot.M.sup.+, wherein R.sup.4 is hydrogen or methyl, (e) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.2M.sup.+, (f) --CH(R.sup.4)--PO(O.sup.-).sub.2 .cndot.D.sup.2+, (g) --CO--CH.sub.2 CH.sub.2 --CO.sub.2.sup.- .cndot.M.sup.+, (h) --CH(CH.sub.3)--O--CO--R.sup.5, wherein R.sup.5 is selected from the group consisting of: ##STR18## and Y is --O--; Z is hydrogen or C.sub.1-4 alkyl. 3. The compound of claim 1 wherein Z is C.sub.1-4 alkyl. 4. the compound of claim 1 wherein Z is --CH.sub.3. 5. The compound of claim 1 wherein A is --CH.sub.2 -- or --CH(CH.sub.3)--. 6. The compound of claim 1 wherein --B is selected from the group consisting of: ##STR19## 7. The compound of claim 1 wherein --A--B is selected from the group consisting of: ##STR20## 8. The compound of claim 1 wherein X is selected from the group consisting of: (a) --PO(O.sup.-).sub.2 .cndot.2M.sup.+, wherein M.sup.+ is a pharmaceutically acceptable monovalent counterion, and (b) --PO(O.sup.-).sub.2 .cndot.D.sup.2+, wherein D.sup.2+ is a pharmaceutically acceptable divalent counterion. 9. The compound of claim 1 of the structural formula II: ##STR21## or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 of the structural formula III: ##STR22## or a pharmaceutically acceptable salt thereof. 11. A compound which is selected from the group consisting of: (1) 2-(S)-(3,5-bis(trifluoromethyl)benzyloxy)-3-(S)-phenyl-4-(3-(5-oxo-1H,4H-1 ,2,4-triazolo)methyl)morpholine N-oxide; (2) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(4-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (3) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(1-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (4) 2-(R)-1(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl -4-(3-(2-monophosphoryl-5-oxo-1H-1,2,4-triazolo)methyl)morpholine; (5) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-4-fluoro)-pheny l-4-(3-(5-oxyphosphoryl-1H-1,2,4-triazolo)methyl)morpholine; (6) 2-(S)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phen yl-4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methyl)morpholine; or a pharmaceutically acceptable salt thereof. 12. The compound of claim 11 wherein the pharmaceutically acceptable salt is the bis(N-methyl-D-glucamine) salt. 13. A compound which is selected from the group consisting of: ##STR23## wherein K.sup.+ is a pharmaceutically acceptable counterion. 14. A compound which is: 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl -4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methylmorpholine; or a pharmaceutically acceptable salt thereof. 15. The compound of claim 14 wherein the pharmaceutically acceptable salt is the bis(N-methyl-D-glucamine) salt. 16. A compound which is 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl -4-(3-(1-phosphoryl-5-oxo-4H-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine). 17. A compound which is: ##STR24## wherein K.sup.+ is a pharmaceutically acceptable counterion. 18. The compound of claim 17 wherein K.sup.+ is N-methyl-D-glucamine. 19. A compound which is: ##STR25## 20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of the compound of claim 1. 21. The pharmaceutical composition of claim 20 wherein the pharmaceutically acceptable carrier comprises water. 22. The pharmaceutical composition of claim 20 wherein the pharmaceutically acceptable carrier comprises a physiologically acceptable saline solution. 23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound which is: ##STR26## 24. A method for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in a mammal which comprises the administration to the mammal of the compound of claim 1 in an amount that is effective for antagonizing the effect of substance P at its receptor site or for the blockade of neurokinin-1 receptors in the mammal. 25. A method of treating or preventing pain or nociception which comprises the administration to the mammal of an effective amount of the compound of claim 1.